Erratum: Correction (The Journal of Allergy and Clinical Immunology (2016) 137(4) (1079–1090) (S0091674916001263) (10.1016/j.jaci.2015.12.1318));Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study

Journal of Allergy and Clinical Immunology

Volumn 137, Issue 4, 2016, Pages 1079-1090

  Krueger, James ^a   Clark, James D ^b   Suárez Fariñas, Mayte ^a   Fuentes Duculan, Judilyn ^a   Cueto, Inna ^a   Wang, Claire Q ^a   Tan, Huaming ^b   Wolk, Robert ^b   Rottinghaus, Scott T ^b   Whitley, Maryann Z ^b   Valdez, Hernan ^b   Von Schack, David ^b   O'Neil, Shawn P ^b   Reddy, Padmalatha S ^b   Tatulych, Svitlana ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

IL 17; IL 22 family; IL 23; inflammation; Janus kinase; keratinocyte; phosphorylated signal transducer and activator of transcription; psoriasis; TH17 cell; tofacitinib

Indexed keywords

BETA DEFENSIN 4; BETA DEFENSIN 4A; CYTOKERATIN 16; GLYCOPROTEIN P 15095; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 19; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 37; KI 67 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN S 100; STAT1 PROTEIN; STAT3 PROTEIN; TOFACITINIB; TRANSCRIPTOME; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CD3+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPIDERMAL THICKNESS; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MICROARRAY ANALYSIS; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKINFOLD THICKNESS; ADOLESCENT; ADULT; AGED; BIOPSY; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PSORIASIS; SIGNAL TRANSDUCTION; SKIN; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BIOPSY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KERATINOCYTES; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84963967684     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.05.002     Document Type: Erratum

References (25)

1. M.P. Schön, and W.H. Boehncke Psoriasis N Engl J Med 352 2005 1899 1912
2. G.K. Perera, P. Di Meglio, and F.O. Nestle Psoriasis Annu Rev Pathol 7 2012 385 422
3. H. Bachelez, P.C.M. van de Kerkhof, R. Strohal, A. Kubanov, F. Valenzuela, J.H. Lee, and et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial Lancet 386 2015 552 561
4. R. Bissonnette, L. Iversen, H. Sofen, C.E.M. Griffiths, P. Foley, R. Romiti, and et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial Br J Dermatol 172 2015 1395 1406
5. K.A. Papp, A. Menter, M. Abe, B. Elewski, S. Feldman, A. Gottlieb, and et al. Two phase 3 studies of oral tofacitinib in patients with moderate to severe plaque psoriasis: 16-week efficacy and safety results J Am Acad Dermatol 72 suppl 1 2015 AB66
6. D.M. Meyer, M.I. Jesson, X. Li, M.M. Elrick, C.L. Funckes-Shippy, J.D. Warner, and et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis J Inflamm (Lond) 7 2010 41
7. K. Ghoreschi, M.I. Jesson, X. Li, J.L. Lee, S. Ghosh, J.W. Alsup, and et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550) J Immunol 186 2011 4234 4243
8. A. Chiricozzi, E. Guttman-Yassky, M. Suarez-Fariñas, K.E. Nograles, S. Tian, I. Cardinale, and et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis J Invest Dermatol 131 2011 677 687
9. A. Chiricozzi, R. Saraceno, M.S. Chimenti, E. Guttman-Yassky, and J.G. Krueger Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? Expert Opin Ther Targets 18 2014 513 525
10. A.S. Lønnberg, C. Zachariae, and L. Skov Targeting of interleukin-17 in the treatment of psoriasis Clin Cosmet Investig Dermatol 7 2014 251 259
11. P. Mudigonda, T. Mudigonda, A.N. Feneran, H.S. Alamdari, L. Sandoval, and S.R. Feldman Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis Dermatol Online J 18 2012 1
12. C.B. Russell, H. Rand, J. Bigler, K. Kerkof, M. Timour, E. Bautista, and et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody J Immunol 192 2014 3828 3836
13. M. Suárez-Fariñas, M.A. Lowes, L.C. Zaba, and J.G. Krueger Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA) PLoS One 5 2010 e10247
14. S. Tian, J.G. Krueger, K. Li, A. Jabbari, C. Brodmerkel, M.A. Lowes, and et al. Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease PLoS One 7 2012 e44274
15. A. Jabbari, M. Suárez-Fariñas, S. Dewell, and J.G. Krueger Transcriptional profiling of psoriasis using RNA-seq reveals previously unidentified differentially expressed genes J Invest Dermatol 132 2012 246 249
16. J. Fuentes-Duculan, M. Suárez-Fariñas, L.C. Zaba, K.E. Nograles, K.C. Pierson, H. Mitsui, and et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis J Invest Dermatol 130 2010 2412 2422
17. The R Foundation. The R Project for Statistical Computing. 2015. Available at: http://www.r-project.org/. Accessed July 8, 2015.
18. Bioconductor. Bioconductor open source software for bioinformatics. 2015. Available at: http://www.bioconductor.org/. Accessed July 8, 2015.
19. N.J. Logsdon, A. Deshpande, B.D. Harris, K.R. Rajashankar, and M.R. Walter Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines Proc Natl Acad Sci U S A 109 2012 12704 12709
20. A.M. Foster, J. Baliwag, C.S. Chen, A.M. Guzman, S.W. Stoll, J.E. Gudjonsson, and et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin J Immunol 192 2014 6053 6061
21. X. Teng, Z. Hu, X. Wei, Z. Wang, T. Guan, N. Liu, and et al. IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production J Immunol 192 2014 1815 1823
22. M.A. Lowes, C.B. Russell, D.A. Martin, J.E. Towne, and J.G. Krueger The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses Trends Immunol 34 2013 174 181
23. W.R. Heath, and F.R. Carbone The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells Nat Immunol 14 2013 978 985
24. M.E. Dowty, M.I. Jesson, S. Ghosh, J. Lee, D.M. Meyer, S. Krishnaswami, and et al. Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis J Pharmacol Exp Ther 348 2014 165 173
25. M. Dowty, T. Lin, L. Wang, J. Jussif, B. Juba, L. Li, and et al. Lack of differentiation of Janus kinase inhibitors in rheumatoid arthritis based on Janus kinase pharmacology and clinically meaningful concentrations Ann Rheum Dis 73 suppl 2 2014 116